Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor analog filgrastim. It serves to stimulate the level of white blood cells. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours). Multiple major pharma companies have been busy developing biosimilar drugs of the the […]
PEGylated pyrene derivatives can be used for the surface functionalization of carbon nanotubes and graphenes via the strong (close to irreversible) pi-pi stacking between the pyrene and the aromatic rings on single wall and multi-walled carbon nanotubes. Pyrene is conjugated to PEG through a very stable amide bond. It is a very simple process that […]
To date, eleven PEGylated proteins, antibody fragments, oligonucleotides, and small molecules have been approved by FDA are on the market, including PEGylated bovine adenosine deaminase: pegademase bovine (Adagen); and PEGylated l-asparaginase: pegaspargase (Oncaspar); PEGylated products of interferon-alpha (IFN-alpha): peginterferon-2b (PegIntron) and peginterferon-2a (Pegasys); PEGylated granulocyte colony stimulating factor (GCSF): pegfilgrastim (Neulasta); PEGylated growth hormone receptor […]
In March 2015, the FDA approved the first biosimilar drug for use in the United States. The drug called Zarxio, produced by Sandoz, is used to help prevent infections in cancer patients receiving chemotherapy, and it is a biosimilar alternative to an existing protein biologic drug called Neupogen made by Amgen. In reviewing the FDA’s […]
